Related Experiment Video
Updated: Apr 26, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
The interaction of CuInS2 /ZnS/TGA quantum dots with tyrosine kinase inhibitor and its application
Shenghua Liao1, Yu Huang, Jiaxin Zuo
1Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, Nanjing, 211198, China; Department of Analytical Chemistry, China Pharmaceutical University, Nanjing, 211198, China.
Abstract:
The interactions between thioglycolic acid-capped-CuInS2 /ZnS quantum dots (CuInS2 /ZnS/TGA QDs) and tyrosine kinase inhibitor (TKI) were investigated using fluorescence, ultraviolet-visible spectrometry and Fourier transform infrared spectrometry. The results indicated that the fluorescence intensity of CuInS2 /ZnS/TGA could be quenched by imatinib, dasatinib, nilotinib, gefitinib and erlotinib, which hinted that CuInS2 /ZnS/TGA QDs could be used in the detection of TKI in active pharmaceutical ingredients (API). Calibration curves showed good linear correlation and low detection limits. The average recovery was between 98 and 102%. Moreover, the nature of the fluorescence quenching mechanism of CuInS2 /ZnS/TGA QDs by TKI was discussed. A ground state complex was formed by hydrogen bonding between the carboxyl group of CuInS2 /ZnS/TGA QDs and the amino group of TKI. This led to an increase in non-radiative transition and fluorescence quenching of CuInS2 /ZnS/TGA QDs.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Receptor Tyrosine Kinases

